Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

MMJ Recs

NOVEMBER 20, 2023

Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronic pain conditions such as arthritis, fibromyalgia, and cancer-related pain. Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

The Cannigma

MAY 9, 2023

However, in 2019, the Jordanian government announced its plans to conduct clinical trials on the use of cannabis for medical purposes. However, the government’s recent announcement of clinical trials on medical cannabis could be a sign of change in the future.

Law 52

Law Clinical Trials Chronic Pain Recreational 52

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

TheAnswerPage

JUNE 29, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

TheAnswerPage

JANUARY 9, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

JULY 27, 2021

and its Scientific Advisory Board, the Organization Publishes New Real-World Study on Epilepsy and CBD. His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 105

Data Epilepsy Research and Development Clinical Trials 105

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. Current Texas Medical Marijuana Regulations CBD laws in Texas are governed by the Compassionate Use Program.

Law 52

Law Clinical Trials Dispensary Programs 52

TheAnswerPage

JULY 13, 2021

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

SEPTEMBER 9, 2021

MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

AUGUST 17, 2021

We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. percent, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial of 24.5 Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

MMJ Recs

JULY 5, 2024

In states where it is legal, dispensaries report increasing sales of THC-infused products aimed at alleviating various health conditions. Understanding THC’s mechanisms and clinical implications is crucial as researchers continue to uncover its therapeutic potential and limitations in medical settings.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

The Cannigma

MARCH 7, 2022

CBN’s ability to target CB2 receptors, in comparison to THC (which prefers the CB1 receptor), gives it better credibility in treating autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

United Patients Group

JANUARY 8, 2023

Cannabis has also been used for centuries to treat gastrointestinal disorders, epilepsy, rheumatism and malaria. Cannabis has been shown to be an effective treatment for a variety of conditions caused by bacteria, viruses and fungi. Ancient Chinese texts and Ayurvedic texts describe its use to treat inflammation, pain and spasms.

Blood Pressure 122

Blood Pressure Sleep Cannabinoids Clinical Trials 122

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

SpeedWeed

MARCH 30, 2021

Anthony Ordman is Honorary Medical Director of Integro Medical Clinics – one of the 20-plus private clinics to have emerged since the law change in 2018. He would like to see the registry opened up to the private sector and believes the restricted conditions available for treatment through the NHS will limit its effectiveness.

Data 52

Data Patients Clinical Trials Business 52

MGC Pharma

FEBRUARY 20, 2018

Cannabis is an effective tool for the treatment of topical skin conditions In a recent study by undertaken by MGC Pharma, our dermatologists found that CBD is effective in providing relief for relief for dry, red, flakey, oily and acne prone skin through CBD skincare.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

AUGUST 24, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to treat aging and longevity, autoimmune diseases, and COVID-19- associated depression and cytokine elevation.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

NOVEMBER 25, 2021

Epilepsy Treatment. The Food and Drug Administration (FDA) recently approved the use of CBD to help treat the condition in individuals as young as two years old. This study is, of course, well-vetted, and has offered plenty of hope to sufferers of epilepsy. Ease Opioid Addiction. Help with Depression and Anxiety.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. Available at: www.fda.gov/media/131878/download.

CBD 144

CBD Seed-To-Sale Food Access 144

The Joint Blog

JANUARY 31, 2021

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. ml twice daily. Case presentation.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

Cannabis Law Report

AUGUST 19, 2021

Faced with booming sales, professor Sagnik Bhattacharyya, who researches psychotic and substance abuse disorders at King’s College London, says clinical trials are needed. ” Despite those concerns, Joe Oliver, head of British-based cannabidiol firm LDN CBD, says his products help those with chronic illness. .

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Cannabis Law Report

AUGUST 26, 2019

Over the years, research has generated results to suggest that marijuana benefits in the treatment of some conditions. The drug for treating such conditions involves a purified form of CBD. The approval is based on the research and clinical trials. Let us have a look at those. Chronic pain. CBD occurs in cannabis.

Chronic Pain 45

Chronic Pain Clinical Trials Epilepsy Conditions 45

Cannabis Law Report

DECEMBER 23, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities, but also challenges to anyone operating in the space. The author has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which could have a large impact on the medicinal cannabis space.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., This is because Epidiolex has been proven an effective treatment after going through various clinical trials. after its consumption.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 5, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

OCTOBER 19, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Canna Care Docs

DECEMBER 16, 2020

Medical marijuana is the use of the marijuana plant or its chemicals to treat various diseases or conditions. What conditions is medical marijuana helpful for? While research is ongoing, existing studies and anecdotal evidence show that medical cannabis is useful for a variety of conditions, both physical and psychiatric.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Medicinal Marijuana Association

AUGUST 27, 2019

Together with the cell’s receptors, these compounds work to protect against many conditions as well as syndromes. The long list of medical conditions which medical cannabis helps to alleviate is all thanks to the revolutionary discoveries made by Prof. The important discoveries made by Prof.

Research and Development 66

Research and Development Clinical Trials Patients Epilepsy 66

Cannabis Law Report

DECEMBER 1, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 22, 2021

At 8,000 times the potency of regular CBD, we believe that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer’s, psychosis, neuropathic pain, addiction, and anxiety. Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

NOVEMBER 18, 2021

“Oravax has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial for its oral COVID-19 vaccine, and preparations to begin the trial are underway. Oravax is also preparing to commence clinical trials in Israel.”.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55